CNS prophylaxis in DLBCL time to say goodbye?

In this issue of Blood, Orellana-Noia et al report that central nervous system (CNS) relapse rates following either intrathecal (IT) or systemic (IV) adminis-tration of methotrexate (MTX) are not significantly different, shedding doubt on the overall efficacy of both approaches.(1)

Automated summary

This article reports that there is no significant difference in central nervous system relapse rates between intrathecal and systemic administration of methotrexate, casting doubt on the overall efficacy of both approaches.